MERION STATION, Pa.,
Dec. 7, 2015 /PRNewswire/ --
American Residential Properties, Inc. (NYSE: ARPI)
The firm is investigating potential claims against the Board of
Directors of American Residential Properties, Inc. (NYSE: ARPI) for
possible breaches of fiduciary duty and other violations in
connection with the merger with American Homes 4 Rent (NYSE:
AMH).
Under the merger agreement, at closing, each share of American
Residential Properties common stock and each limited partnership
unit in its operating partnership will be exchanged for 1.135
common shares or limited partnership units of American Homes 4
Rent, representing a current value per share/unit of American
Residential Properties of $19.01
based on American Homes 4 Rent closing price on December 2, 2015, a 19.8% premium over the volume
weighted average closing price of American Residential Properties
common stock over the 20 trading days ending on December 2, 2015, and an 8.7% premium over
American Residential Properties' closing price on December 2, 2015. The exchange ratio is not
subject to adjustment.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
HF Financial Corp. (Nasdaq: HFFC)
The firm is investigating potential claims against the board of
directors of HF Financial Corp. ("HF Financial" or the "Company")
(HFFC) concerning the proposed acquisition of the Company by Great
Western Bancorp, Inc. ("Great Western").
Under the terms of the offer, Great Western would acquire HF
Financial in a transaction valued at approximately $139.5 million. Pursuant to the deal, HF
Financial stockholders would receive either 0.65 shares of Great
Western or $19.50 in cash per share
of HF Financial owned.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
Mattson Technology Inc. (Nasdaq: MTSN)
The firm has commenced an investigation into the fairness of the
sale of Mattson Technology, Inc. to Beijing E-Town Dragon
Semiconductor Industry Investment Center (Limited Partnership) for
$3.80 in cash per share.
Mattson Technology, Inc. (NASDAQ: MTSN) and Beijing E-Town
Dragon Semiconductor Industry Investment Center (Limited
Partnership) ("E-Town Dragon"), jointly announced that they have
entered into a definitive merger agreement under which E-Town
Dragon will acquire all of the outstanding shares of Mattson for
$3.80 per share in cash. The
transaction price represents a 55 percent premium to the 30-trading
day average closing price for the period ending December 1, 2015, a 23 percent premium to
Mattson's closing stock price on December 1,
2015, and values Mattson's equity at approximately
$300 million on a fully diluted
basis.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
Osiris Therapeutics, Inc. (Nasdaq: OSIR)
The Law Office is investigating Osiris Therapeutics, Inc.
(Nasdaq: OSIR) concerning possible violations of federal securities
laws by the Company and/or certain of its officers and
directors.
According to a complaint filed, between May 12, 2014 thru November
20, 2015 ("Class Period")the defendants issued false and
misleading statements to investors and/or failed to disclose that:
(1) Osiris improperly recognized revenue under contracts it had
with its distributors; (2) Osiris' disclosure controls and
procedures were not effective as of December
31, 2014, March 31, 2015, and
June 30, 2015; and (3) as a result,
defendants' statements about Osiris' business and prospects were
materially false and misleading and/or lacked a reasonable basis at
all relevant times.
The Company announced that it is determined to correct the
revenue recognition for three contracts which will result in a
decrease in product revenues of $1.8
million in the first quarter of 2015, a decrease in product
revenues of $1.0 million in the
second quarter, an increase in product revenues of $0.8 million in the third quarter of 2015 and a
decrease in product revenues of $1.1
million in 2014. When the truth was revealed, shares dropped
causing investors harm.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
XBiotech Inc. (Nasdaq: XBIT)
The Law Office is investigating XBiotech Inc. (Nasdaq: XBIT)
concerning possible violations of federal securities laws by the
Company and/or certain of its officers and directors.
According to a complaint filed, between April 15, 2015 and November 23, 2015, ("Class Period") defendants
made materially false and misleading statements, and omitted
materially adverse facts, about the Company's business, operations
and prospects. As a result of defendants' alleged false and
misleading statements, the price of Company's stock was
artificially inflated.
On November 23, 2015, the Company
issued a press release detailing problems with the number of
patients in its Phase III study. According to the release, the
Company reported that data cleaning had revealed a fewer number of
per protocol patients available for primary endpoint evaluation.
The Company indicated that the irregularities found compromised
data from 72 patients in the study.
On this news, shares in XBiotech dropped over 33%, closing at
$8.75 per share on November 24, 2015, on heavy trading volume.
If you would like to learn more about the investigation or you
wish to discuss this matter, please contact Marc S. Henzel (610) 660-8000, email at
Mhenzel@Henzellaw.com, or visit the firms website at
www.henzellaw.com.
The Law Offices of Marc S. Henzel
is a national shareholder litigation firm representing shareholders
& investors in various areas of securities laws including but
not limited to; class actions, derivatives, transactional
(buyouts/mergers/acquisitions) and FINRA & NYSE
Arbitrations.
Attorney advertising. © 2015 Law Offices of Marc S. Henzel. The law firm responsible
for this advertisement is Marc S.
Henzel. Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
Contact:
Law Offices of Marc S. Henzel
Marc S. Henzel
Email: Mhenzel@Henzellaw.com
Phone 610-660-8000
Website: www.henzellaw.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/law-offices-of-marc-s-henzel-commences-investigations-of-american-residential-properties-inc-hf-financial-corp-mattson-technology-inc-osiris-therapeutics-inc-and-xbiotech-inc-300188650.html
SOURCE Law Offices of Marc S.
Henzel